View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 30, 2022

aptaTargets initiates dosing with ApTOLL in Phase Ib Covid-19 trial

Analysing the safety and efficacy of ApTOLL in hospitalised Covid-19 patients is the aim of the trial.

aptaTargets has reported the dosing of the first subject in a Phase Ib clinical trial of its drug, ApTOLL, to treat Covid-19 patients admitted to the hospital.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The first subject was dosed at the University Hospital La Princesa in Madrid, Spain.

Named aptaCovid, the blind, randomised, multicentre, placebo-controlled trial will enrol 30 Covid-19 patients admitted to the hospital and are at cytokine storm syndrome development risk.

Cytokine storm syndrome is an uncontrolled inflammatory process of the ailment. 

Analysing the safety and efficacy of ApTOLL is the aim of the trial.

The trial was also launched at three other Spanish hospitals, Ramón y Cajal, Clínico San Carlos of Madrid and the University Hospital of Burgos.

Subjects in the trial will be given three intravenous drug doses for three days and their clinical progress and inflammatory process development will be evaluated.

The company anticipates reporting the initial data from the trial in the third quarter of this year. 

On obtaining positive findings, aptaTargets will progress ApTOLL to Phase II trials.

Last year, the Spanish Agency of Medicines and Medical Products (AEMPS) granted clearance to commence the trial, which also obtained funds from the Spanish Ministry of Science and Innovation agency and the Centre for the Development of Industrial Technology.

aptaTargets CEO David Segarra said: “We are very happy that this aptaCovid trial has included the first patient and that it is taking place at leading hospitals in infectious diseases. 

“ApTOLL offers high potential to be an effective and safe treatment option in patients hospitalised for Covid-19.”

In February this year, the company joined a consortium to advance ribonucleic acid oligonucleotide-based therapy development for treating rare diseases.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU